# THERAPEUTICS FOR EMERGING HUMAN ENTEROVIRUSES

> **NIH NIH N01** · HDT BIO CORPORATION · 2022 · $1,499,422

## Abstract

This is a phase II SBIR Contract to develop broad spectrum monoclonal antibodies against enteroviruses.  EV-D68 causes respiratory and neurological diseases mainly in young children and implicated to be a major cause for acute flaccid myelitis (AFM). There are no therapeutics or vaccines against EV-D68. EV-D68 is a member of picornavirus family, a priority pathogen because of their high pandemic potential.

## Key facts

- **NIH application ID:** 10684970
- **Project number:** 75N93022C00017-0-9999-1
- **Recipient organization:** HDT BIO CORPORATION
- **Principal Investigator:** KANDYMA SAR
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $1,499,422
- **Award type:** —
- **Project period:** 2022-07-01 → 2025-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10684970

## Citation

> US National Institutes of Health, RePORTER application 10684970, THERAPEUTICS FOR EMERGING HUMAN ENTEROVIRUSES (75N93022C00017-0-9999-1). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10684970. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*